Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Bioinformatics ; 37(12): 1761-1762, 2021 07 19.
Artículo en Inglés | MEDLINE | ID: mdl-33045068

RESUMEN

MOTIVATION: The first cases of the COVID-19 pandemic emerged in December 2019. Until the end of February 2020, the number of available genomes was below 1000 and their multiple alignment was easily achieved using standard approaches. Subsequently, the availability of genomes has grown dramatically. Moreover, some genomes are of low quality with sequencing/assembly errors, making accurate re-alignment of all genomes nearly impossible on a daily basis. A more efficient, yet accurate approach was clearly required to pursue all subsequent bioinformatics analyses of this crucial data. RESULTS: hCoV-19 genomes are highly conserved, with very few indels and no recombination. This makes the profile HMM approach particularly well suited to align new genomes, add them to an existing alignment and filter problematic ones. Using a core of ∼2500 high quality genomes, we estimated a profile using HMMER, and implemented this profile in COVID-Align, a user-friendly interface to be used online or as standalone via Docker. The alignment of 1000 genomes requires ∼50 minutes on our cluster. Moreover, COVID-Align provides summary statistics, which can be used to determine the sequencing quality and evolutionary novelty of input genomes (e.g. number of new mutations and indels). AVAILABILITY AND IMPLEMENTATION: https://covalign.pasteur.cloud, hub.docker.com/r/evolbioinfo/covid-align. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.


Asunto(s)
COVID-19 , Programas Informáticos , Genoma , Humanos , Pandemias , SARS-CoV-2
2.
PLoS Comput Biol ; 17(8): e1008873, 2021 08.
Artículo en Inglés | MEDLINE | ID: mdl-34437532

RESUMEN

Drug resistance mutations (DRMs) appear in HIV under treatment pressure. DRMs are commonly transmitted to naive patients. The standard approach to reveal new DRMs is to test for significant frequency differences of mutations between treated and naive patients. However, we then consider each mutation individually and cannot hope to study interactions between several mutations. Here, we aim to leverage the ever-growing quantity of high-quality sequence data and machine learning methods to study such interactions (i.e. epistasis), as well as try to find new DRMs. We trained classifiers to discriminate between Reverse Transcriptase Inhibitor (RTI)-experienced and RTI-naive samples on a large HIV-1 reverse transcriptase (RT) sequence dataset from the UK (n ≈ 55, 000), using all observed mutations as binary representation features. To assess the robustness of our findings, our classifiers were evaluated on independent data sets, both from the UK and Africa. Important representation features for each classifier were then extracted as potential DRMs. To find novel DRMs, we repeated this process by removing either features or samples associated to known DRMs. When keeping all known resistance signal, we detected sufficiently prevalent known DRMs, thus validating the approach. When removing features corresponding to known DRMs, our classifiers retained some prediction accuracy, and six new mutations significantly associated with resistance were identified. These six mutations have a low genetic barrier, are correlated to known DRMs, and are spatially close to either the RT active site or the regulatory binding pocket. When removing both known DRM features and sequences containing at least one known DRM, our classifiers lose all prediction accuracy. These results likely indicate that all mutations directly conferring resistance have been found, and that our newly discovered DRMs are accessory or compensatory mutations. Moreover, apart from the accessory nature of the relationships we found, we did not find any significant signal of further, more subtle epistasis combining several mutations which individually do not seem to confer any resistance.


Asunto(s)
Macrodatos , Farmacorresistencia Viral/genética , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , VIH-1/efectos de los fármacos , VIH-1/genética , Aprendizaje Automático Supervisado , África , Fármacos Anti-VIH/farmacología , Teorema de Bayes , Biología Computacional , Bases de Datos Genéticas , Árboles de Decisión , Epistasis Genética , Genes Virales , Transcriptasa Inversa del VIH/antagonistas & inhibidores , Transcriptasa Inversa del VIH/química , Transcriptasa Inversa del VIH/genética , Humanos , Modelos Logísticos , Modelos Genéticos , Mutación , Reino Unido
3.
iScience ; 25(11): 105305, 2022 Nov 18.
Artículo en Inglés | MEDLINE | ID: mdl-36339268

RESUMEN

Sequencing errors continue to pose algorithmic challenges to methods working with sequencing data. One of the simplest and most prevalent techniques for ameliorating the detrimental effects of homopolymer expansion/contraction errors present in long reads is homopolymer compression. It collapses runs of repeated nucleotides, to remove some sequencing errors and improve mapping sensitivity. Though our intuitive understanding justifies why homopolymer compression works, it in no way implies that it is the best transformation that can be done. In this paper, we explore if there are transformations that can be applied in the same pre-processing manner as homopolymer compression that would achieve better alignment sensitivity. We introduce a more general framework than homopolymer compression, called mapping-friendly sequence reductions. We transform the reference and the reads using these reductions and then apply an alignment algorithm. We demonstrate that some mapping-friendly sequence reductions lead to improved mapping accuracy, outperforming homopolymer compression.

4.
Curr Opin Virol ; 51: 56-64, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-34597873

RESUMEN

Drug resistance mutations appear in HIV under treatment pressure. Resistant variants can be transmitted to treatment-naive individuals, which can lead to rapid virological failure and can limit treatment options. Consequently, quantifying the prevalence, emergence and transmission of drug resistance is critical to effectively treating patients and to shape health policies. We review recent bioinformatics developments and in particular describe: (1) the machine learning approaches intended to predict and explain the level of resistance of HIV variants from their sequence data; (2) the phylogenetic methods used to survey the emergence and dynamics of resistant HIV transmission clusters; (3) the impact of deep sequencing in studying within-host and between-host genetic diversity of HIV variants, notably regarding minority resistant variants.


Asunto(s)
Biología Computacional , Farmacorresistencia Viral/genética , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , VIH/efectos de los fármacos , VIH/genética , Mutación , VIH/clasificación , Humanos , Filogenia
5.
C R Biol ; 2020 Nov 24.
Artículo en Inglés | MEDLINE | ID: mdl-33274614

RESUMEN

SARS-CoV-2 is the virus responsible for the global COVID19 pandemic. We review what is known about the origin of this virus, detected in China at the end of December 2019. The genome of this virus mainly evolves under the effect of point mutations. These are generally neutral and have no impact on virulence and severity, but some appear to influence infectivity, notably the D614G mutation of the Spike protein. To date (30/09/2020) no recombination of the virus has been documented in the human host, and very few insertions and deletions. The worldwide spread of the virus was the subject of controversies that we summarize, before proposing a new approach free from the limitations of previous methods. The results show a complex scenario with, for example, numerous introductions to the USA and returns of the virus from the USA to certain countries including France.


Le SARS-CoV-2 est le virus responsable de la pandémie mondiale de COVID19. On dresse ici un bilan de ce qui est connu sur l'origine de ce virus, détecté en Chine fin décembre 2019. Le génome de ce virus évolue sous l'effet de mutations ponctuelles. Celles-ci sont généralement neutres et sans impact sur la virulence et la sévérité, mais certaines semblent influer sur l'infectiosité, notamment la mutation D614G de la protéine Spike. A l'inverse, on n'a à ce jour (30/09/2020) documenté aucune recombinaison du virus chez l'hôte humain, et très peu d'insertions et de délétions. La propagation mondiale du virus a fait l'objet de polémiques sur lesquelles nous revenons, avant de proposer une nouvelle approche débarrassée des limites des méthodes précédentes. Les résultats montrent une propagation complexe avec, par exemple, de très nombreuses introductions aux USA et des retours du virus depuis les USA vers certains pays dont la France.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA